In this review:
This review discusses the evidence in support of the use of ticagrelor (Brilinta™), a reversible, selective P2Y12-receptor
antagonist that was recently approved by Medsafe New Zealand for the prevention of atherothrombotic events in patients
aged ≥18 years with acute coronary syndrome (ACS), including patients managed medically, and those who are managed
with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).
Download PDF